Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease

Miyauchi, Katsumi; Daida, Hiroyuki

doi:10.1253/circj.cj-10-0565

Cited by 25 publications

(19 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 We agree completely with their opinion in a specific clinical setting, or for patients with higher cardiovascular risk such as Caucasians and Japanese with multiple coronary risk factors. Coronary plaque regression may bring cardiovascular risk reduction by logical or even syllogistic ways of thinking.…”

Section: Authors' Comments On the Pro-side Authorssupporting

confidence: 67%

"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -

Sakamoto

Ogawa

2010

Circ J

View full text Add to dashboard Cite

Section: Authors' Comments On the Pro-side Authorssupporting

confidence: 67%

"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -

Sakamoto

Ogawa

2010

Circ J

View full text Add to dashboard Cite

“…As with the previous JAS guidelines of 2007, an LDL-C goal of ＜120 mg/dL has been set for high-risk primary prevention patients, with an LDL-C goal of ＜100 mg/dL recommended for secondary prevention patients. Whether more stringent, Western-style lipid targets are required in Japan, and whether intensive treatment to achieve these goals would provide a clear clinical benefit in Japanese patients, is the subject of much debate 66,67) . The proportion of secondary prevention patients who reach recommended lipid goals in Japan is traditionally very low (20%-40%) 68,69) .…”

Section: Effects On Cardiovascular Disease In Patients Withmentioning

confidence: 99%

Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience

Koya

Campese

2013

JAT

View full text Add to dashboard Cite

Diabetes is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in developed nations, including Japan and the United States. Japan has the unenviable distinction of having one of the world's highest rates of dialysis: in 2011, there were over 300,000 dialysis patients (2,383 per million people), with diabetic patients accounting for almost half of all incident cases. Concomitance of CKD and diabetes predicts a greater risk of cardiovascular disease (CVD) than either condition in isolation. Hence, appropriate management of modifiable cardiovascular (CV) risk factors, including dyslipidemia, is paramount in this high-risk group. The United States and Japan have distinct approaches to cholesterol management, with more stringent therapeutic targets for lipid control advocated in US guidelines. However, upward trends in cholesterol levels and coronary heart disease incidence in Japan may provide justification for more intensive CV risk factor management strategies by Japanese physicians to achieve maximum benefit. Attainment of recommended lipid goals in Japan is poor, particularly in patients with diabetes and/or CKD in whom CV risk factors are often undertreated. Statin therapy has been shown to be safe and effective in reducing CV risk in patients with diabetes and/or CKD stages 1-5. Moreover, statins may impart a renoprotective effect by preventing or delaying progressive loss of kidney function. This review summarizes evidence from studies in Western and Japanese populations to highlight the CV and renal benefits of lipid-lowering agents in CKD patients, including those with diabetes. J Atheroscler

show abstract

“…47 (A) Low-density lipoprotein-cholesterol (LDL-C) levels and plaque volume were significantly reduced by statin treatment. 71 (B) Intravascular ultrasound images before treatment (left panels) and after 6 months (right panels). Atorvastatin (lower right panel) has significantly reduced plaque area whereas no change in the plaque area can be seen in control (upper right panel) 47 (A) Reproduced with permission from Miyauchi et al 71 (B) Reproduced with permission from Okazaki et al 47 significantly reduce serum levels of CRP, which is a nonspecific marker of inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…71 (B) Intravascular ultrasound images before treatment (left panels) and after 6 months (right panels). Atorvastatin (lower right panel) has significantly reduced plaque area whereas no change in the plaque area can be seen in control (upper right panel) 47 (A) Reproduced with permission from Miyauchi et al 71 (B) Reproduced with permission from Okazaki et al 47 significantly reduce serum levels of CRP, which is a nonspecific marker of inflammation. 2,61 In Chinese patients with ACS, early fluvastatin therapy dose-dependently reduced serum concentrations of CRP and tumour necrosis factor-a.…”

Section: Discussionmentioning

confidence: 99%

A review of statin use in patients with acute coronary syndrome in Western and Japanese populations

Miyauchi

Ray

2013

J Int Med Res

Self Cite

View full text Add to dashboard Cite

Early high-dose statin therapy to reduce low-density lipoprotein cholesterol (LDL-C) is associated with improved cardiovascular outcomes in Western patients with stable coronary heart disease or acute coronary syndromes (ACS), but many patients remain undertreated and do not attain LDL-C treatment goals. Early statin therapy has also been shown to improve cardiovascular outcomes in Japanese patients with ACS, and pretreatment with high-dose statin prior to percutaneous coronary intervention has been shown to reduce cardiovascular events in these patients. As is the case in Western populations, many Japanese patients may be undertreated and a residual cardiovascular risk remains. While differences in treatment practice, dosing and genetic factors exist between Japan and Western countries, similarities are also evident when Japanese statin studies are compared with those performed in Western populations. With the increasing prevalence of cardiovascular risk factors in Japan, aggressive statin treatment may be beneficial in achieving optimal cardiovascular outcomes.

show abstract

Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease

Cited by 25 publications

References 45 publications

"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -

"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -

Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience

A review of statin use in patients with acute coronary syndrome in Western and Japanese populations

Contact Info

Product

Resources

About